Clinical trial
Collagenase in the Treatment of Dupuytrens Disease
NCT00260429 · Stony Brook University, Other · Completed
Key facts
| NCT number | NCT00260429 |
|---|---|
| Title | Collagenase in the Treatment of Dupuytrens Disease |
| Official title | Double-blind, Randomized Placebo Controlled Study of the Relative Safety and Efficacy of Collagenase Therapy in the Treatment of Residual-type Dupuytren's Disease. |
| Lead sponsor | Stony Brook University, Other |
| Collaborators | Biospecifics Technologies Corp. Industry Endo Pharmaceuticals |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dupuytren's Disease |
| Intervention type | Biological |
| Interventions | collagenase clostridium histolyticum |
| Enrollment | 38 |
| Start date | Jun 1, 2003 |
| Primary completion | Aug 1, 2005 |
| Completion | Apr 1, 2008 |
| First posted | Dec 1, 2005 |
| Last update posted | Dec 9, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: